← Leaderboards
Xuntian Jiang
Washington University
$2,199,946
Attributed
$2,764,712
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $466K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,764,712 · 2
By mechanism
U01$2,764,712 · 2
Top collaborators
- Frederick R. Maxfield2 shared
- Daniel S Ory2 shared
Most similar at Washington University
Same institution · by research overlap
- Daniel S Ory$14,176,962
- Jean E Schaffer$33,853,860
- Robert J Gropler$22,166,148
- Abhinav K Jha$5,646,069
- McKenna Rae Feltes$260,754
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingBiological MarkersPlasmaDisease ProgressionDefectFoundationsNerve DegenerationPeripheralTreatment EfficacyClinical TrialsResponseOutcome MeasureAffectBeta-GalactosidaseDrug DevelopmentEffective TherapyDiagnosisExhibitsFelis CatusBrainDcnuBone StructureClinical EfficacyClinical Predictors
Grant awards (7)
Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis$354,375
U01 · FY2025 · NS · contact PI
Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis$381,938
U01 · FY2024 · NS · contact PI
Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis$393,750
U01 · FY2023 · NS · contact PI
Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis$393,750
U01 · FY2022 · NS · contact PI
Validation of analytical methods for quantification of a pentasaccharide biomarker in efficacy assessment of AVV treatment for GM1 gangliosidosis$393,750
U01 · FY2021 · NS · contact PI
A Phase 1 Dose Escalation Study of Vorinostat in Niemann-Pick C1 Disease$381,171
U01 · FY2016 · HD
A Phase 1 Dose Escalation Study of Vorinostat in Niemann-Pick C1 Disease$465,978
U01 · FY2015 · HD